天力康透博士品牌怎么样 申请店铺

我要投票 天力康透博士在其他行业中的票数:425 更新时间:2025-08-24
天力康透博士是哪个国家的品牌?「天力康透博士」是 郑州天力康生物科技有限公司 旗下著名品牌。该品牌发源于郑州,由创始人王力军在2016年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力天力康透博士品牌出海!将品牌入驻外推网,定制天力康透博士品牌推广信息,可以显著提高天力康透博士产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

天力康透博士怎么样

国家政策支持

1,中医定向透药疗法已列入国家卫生部和国家发改委《全国医疗服务项目价格目录》和医保项目,项目编码为420000013(PBBA1101)

2,国家中医药管理局(2011版)中医诊疗设备推荐产品目录

3,十二五和十八大明确将“智能精准医疗”作为中国医疗未来发展的重点。

4,国家中医药管理局中医医院医疗设备配置标准(2012年试行)必备设备

5,2014社区康复中心必备配置的基础设备

6,2014市、县级中医院、民族医院能力建设项目中医诊疗设备必选产品 

符合国家政策方向 

1. 随着药品零差价,国家和各省都提倡提高诊疗、服务和治疗收费标准。弥补医院利润亏损部分,国家对已药养医痛下整治药价虚高,药品经销商利润下降,医院大型设备也呈现饱和状态,医院也卓见减少药品的使用比例,医院利润也在减少,各医院都在适应新一轮医改,也在在找新的经济支撑点,送仪器卖耗材医院不投分文,可为科室创收!患者治疗可以刷医保,医院 患者 经销商三方收益。同时对医务人员劳动的认可,并且国家对传统医学加大扶植力度,所以此项目合服国家基本国策。

2. 由国务院办公厅印发的《中医药健康服务发展规划(2015-2020年)》规定:力争全国所有社区卫生服务机构、乡镇卫生院和70%的村卫生室要具备中医药服务能力。明确要求,在基层大力推广发展传统中医特色治疗服务,到2020年,基本建立基层中医服务体系。

3. 医疗门诊取消输液打针减少抗生素使用,中医定向透药疗法可以代替一些抗生素,透皮给药的直达病灶的绿色疗法!市场接受率高!门诊诊所特色诊疗创收项目! 

不受处方限制       

基本医院都限品规和限制销售数量,此项目不会受到限制,所以进医院容易,上量快,并且不受销售量的限制


National policy support 1, Chinese medicine directed transdermal therapy has been listed in the national medical service project price catalogue and medical insurance project of the Ministry of health and the national development and Reform Commission, the project code is 420000013 (pbba1101) 2, the national administration of traditional Chinese medicine (2011 version) recommended product catalogue of Chinese medicine diagnosis and treatment equipment 3, the 12th Five Year Plan and the 18th National Congress of the Communist Party of China definitely regard "intelligent precision medicine" as the future development of Chinese Medicine Focus of the exhibition. 4. The allocation standard of medical equipment of traditional Chinese Medicine Hospital of the State Administration of traditional Chinese medicine (Trial Implementation in 2012) necessary equipment 52014 basic equipment of community rehabilitation center 62014 City, county-level traditional Chinese medicine hospital, national hospital capacity building project of traditional Chinese medicine diagnosis and treatment equipment must be selected products in line with the national policy direction. 1. With the zero price difference of drugs, the state and all provinces advocate to improve diagnosis and treatment, service and treatment Treatment charge standard. In order to make up for the loss of hospital profits, the state regulates the false high price of drugs under the pain of medical care, the profit of drug dealers decreases, the large-scale equipment of the hospital is also saturated, the hospital also significantly reduces the proportion of drugs used, the profit of the hospital is also decreasing, all hospitals are adapting to the new round of medical reform, and are also looking for new economic support points. The hospital that delivers equipment and supplies does not invest in articles, which can be a department Room income! The treatment of patients can be covered by medical insurance, and the benefits of the hospital's patients dealers can be obtained. At the same time, the recognition of medical staff's labor, and the country's efforts to increase support for traditional medicine, so this project conforms to the basic national policy. 2. The development plan of Chinese medicine health service (2015-2020) issued by the general office of the State Council stipulates that all community health service institutions, township health centers and 70% of village health offices in China should have the ability of Chinese medicine service. It is clearly required to vigorously promote the development of traditional Chinese medicine characteristic treatment services at the grass-roots level, and by 2020, basically establish the grass-roots Chinese medicine service system. 3. In the medical clinic, transfusion and injection are cancelled to reduce the use of antibiotics. Traditional Chinese medicine directed transdermal therapy can replace some antibiotics. It is a direct and green therapy of transdermal drug delivery! High market acceptance rate! Outpatient clinic special diagnosis and treatment income generating project! No prescription restrictions. Basic hospitals are limited by product regulations and sales volume. This project will not be limited, so it is easy to enter the hospital, fast in quantity, and not limited by sales volume

本文链接: https://brand.waitui.com/85865df38.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格林美:筹划发行H股股票并在香港联交所上市

36氪获悉,格林美发布公告,经充分研究论证,董事会同意公司发行H股股票并在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况,在股东会决议有效期内(即经公司股东会审议通过之日起24个月或同意延长的其他期限)选择适当的时机和发行窗口完成本次发行上市。截至目前,公司正积极与相关中介机构就本次发行上市的相关工作进行商讨,除本次董事会、监事会审议通过的相关议案外,其他关于本次发行上市的具体细节尚未最终确定。

17分钟前

中信证券:预计未来中国前列腺癌RDC诊疗市场将超100亿元

36氪获悉,中信证券研报表示,创新核药RDC有望解决目前前列腺癌诊疗过程中检测负担大、疗效有限等未被满足临床需求,改变前列腺癌诊疗范式,实现诊疗一体化,提高患者依从性和生存期。目前中国尚无任何RDC上市,市场呈现蓝海状态,海外前列腺癌RDC诊疗产品在2021年上市,2024年市场已接近30亿美元,充分验证了其巨大的商业价值。中信证券认为中国有望复刻海外前列腺癌RDC诊疗市场发展路径,预计未来中国前列腺癌RDC诊疗市场将超100亿元,市场呈现高速增长状态。该行业关键点为核素、配体分子形态、生产配送能力,建议关注在上述条件具有优势的公司。

17分钟前

​锡业股份:上半年净利润10.62亿元,同比增长32.76%

36氪获悉,锡业股份披露2025年半年报,上半年实现营业收入210.93亿元,同比增长12.35%;归属于上市公司股东的净利润10.62亿元,同比增长32.76%;基本每股收益0.626元。

17分钟前

亚世光电:上半年净利润538.04万元,同比下降36.21%

36氪获悉,亚世光电披露2025年半年报,上半年实现营业收入4.32亿元,同比增长30.01%;归属于上市公司股东的净利润538.04万元,同比下降36.21%;基本每股收益0.0331元。

17分钟前

金螳螂:上半年净利润3.58亿元,同比增长3.95%

36氪获悉,金螳螂披露2025年半年报,上半年实现营业收入95.28亿元,同比增长2.49%;归属于上市公司股东的净利润3.58亿元,同比增长3.95%;基本每股收益0.1348元。

17分钟前

本页详细列出关于天力康透博士的品牌信息,含品牌所属公司介绍,天力康透博士所处行业的品牌地位及优势。
咨询